Plantation, Fla., Dec. 16,
2022 /CNW/ - Akumin Inc. (NASDAQ: AKU) (TSX: AKU)
("Akumin" or the "Company") is pleased to announce that
John Wagner and Lawrence Ross Sinclair will join its board of
directors effective January 1, 2023.
Mr. Sinclair will also be appointed a member of the audit committee
of the Company effective January 1,
2023. Mr. Wagner is a nominee of SCW Capital Management, LP
("SCW Capital"), which through its affiliates currently holds an
approximate 12.7% interest in the common stock of Akumin
(calculated on a non-diluted basis).
"We have strengthened our board of directors with the addition
of John Wagner, who represents a
long-term shareholder that believes in our strategic direction and
continues to support the future value creation of our asset base,
and Ross Sinclair, who brings
significant audit and financial reporting experience," said
Riadh Zine, Chairman and Chief
Executive Officer of the Company.
The following are summary biographies for Mr. Wagner and Mr.
Sinclair.
Mr. Wagner is a co-founder and co-managing partner of SCW
Capital which is an equity investment fund focused on domestic
public equities where he focuses on the healthcare technology and
service sectors (2014-present). In addition to SCW Capital, Mr.
Wagner is the co-founder and Managing Partner for Viewside Capital
Partners. Viewside Capital Partners is a private equity firm
focused on growth equity investments in the healthcare technology
and service sectors. Mr. Wagner is currently a member of the
board of directors for D2 Solutions, Benefit Harbor, Strivant
Health, and Flow Therapy. Prior to current roles, Mr. Wagner was
the CFO of Healthcare Payment Specialists, a private equity owned
healthcare IT company (2012-2013), a Partner with Walker Smith
Capital responsible for investments within the healthcare industry
(2003-2012), an Associate in the Healthcare Investment Banking
Group at UBS and an Analyst in the Healthcare Corporate Finance
Group at Bank of America (1999-2003). Mr. Wagner graduated from the
University of Texas with a Bachelor of
Business Administration in Finance.
Mr. Sinclair was a partner with PricewaterhouseCoopers LLP
("PwC") and has more than 25 years of experience as a partner. He
retired from PwC on June 30, 2020 and
has worked since July 2021 as a
Senior Financial Consultant for the Real Estate Group of Fengate
Asset Management and a Trustee with Enterprise REIT since March
2022. Mr. Sinclair has had extensive experience across
several industries including consumer products, retail, real
estate, health care and private equity. He has worked advising on
critical business issues, transactions, and restructurings in
addition to his experience as a lead audit partner on both public
and private enterprises. Mr. Sinclair's experience includes PwC
Canada leadership roles as Income Trust and IPO Services Group
Leader. He has significant experience working with clients on their
capital markets projects and needs including numerous equity, debt
and initial public offering and RTOs. In addition to serving as
the audit partner on many public companies across various
reporting frameworks including US GAAP, and IFRS, Mr. Sinclair was
a designated Trustee on the Continuum REIT IPO in the fall of
2019, a director of Nova Cannabis Inc from its March 2021 RTO to April
2022 and is an Advisory Board member and investor in Arch
Corporation. Mr. Sinclair graduated from the University of Toronto with a Bachelor of Commerce
and is a Chartered Professional Accountant.
About Akumin
Akumin is a national partner of choice for U.S. hospitals,
health systems and physician groups, with comprehensive solutions
addressing outsourced radiology and oncology service-line needs.
Akumin provides (1) fixed-site outpatient diagnostic imaging
services through a network of owned and/or operated imaging
locations; and (2) outpatient radiology and oncology services and
solutions to approximately 1,000 hospitals and health systems
across 48 states. By combining clinical and operational expertise
with the latest advances in technology and information systems,
Akumin facilitates more efficient and effective diagnosis and
treatment for patients and their providers. Akumin's imaging
procedures include MRI, CT, positron emission tomography (PET and
PET/CT), ultrasound, diagnostic radiology (X-ray), mammography, and
other interventional procedures; our cancer care services include a
full suite of radiation therapy and related offerings. For more
information, visit www.akumin.com.
Forward-Looking
Information
Certain information in this press release constitutes
forward-looking information. In some cases, but not necessarily in
all cases, forward-looking information can be identified by the use
of forward-looking terminology such as "plans", "targets",
"expects" or "does not expect", "is expected", "is positioned",
"estimates", "intends", "assumes", "anticipates" or "does not
anticipate" or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might", "will" or "will be taken", "occur" or "be
achieved". In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
information is necessarily based on a number of opinions,
assumptions and estimates that, while considered reasonable by
Akumin as of the date of this press release, are subject to known
and unknown risks, uncertainties, assumptions and other factors
that may cause the actual results, level of activity, performance
or achievements to be materially different from those expressed or
implied by such forward-looking information, including, but not
limited to, the factors described in greater detail in the "Risk
Factors" sections located in (1) Akumin's Annual Report on Form
10-K for the fiscal year ended December 31,
2021, filed with the SEC on March 16,
2022, as amended by Amendment No. 1 to Form 10-K, filed with
the SEC on April 12, 2022 (the "2021
Annual Report"), and (2) Akumin's Quarterly Reports on Form 10-Q
for the quarterly periods ended March 31,
2022, June 30, 2022, and
September 30, 2022, filed with the
SEC on May 10, 2022, August 9, 2022, and November 9, 2022, respectively, which are
available at www.sec.gov and www.sedar.com. These factors are not
intended to represent a complete list of the factors that could
affect Akumin; however, these factors should be considered
carefully. There can be no assurance that such estimates and
assumptions will prove to be correct. The forward-looking
statements contained in this press release are made as of the date
of this press release, and Akumin expressly disclaims any
obligation to update or alter statements containing any
forward-looking information, or the factors or assumptions
underlying them, whether as a result of new information, future
events or otherwise, except as required by law.
View original
content:https://www.prnewswire.com/news-releases/akumin-announces-appointment-of-new-directors-301704930.html
SOURCE Akumin Inc.
